Antidiabetic and hypolipidemic activities of hydroethanolic root extract of Uvaria chamae in streptozotocin induced diabetic albino rats

BMC Complementary and Alternative Medicine

Volumn 16, Issue 1, 2016, Pages

  Emordi, Jonathan Emeka ^a   Agbaje, Esther Oluwatoyin ^b   Oreagba, Ibrahim Adekunle ^b   Iribhogbe, Osede Ignis ^a  

^a AMBROSE ALLI UNIVERSITY   (Nigeria)

^b UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

Diabetes mellitus; Hypoglycemic effects; Hypolipidemic effects; Streptozotocin; Uvaria chamae

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; UNCLASSIFIED DRUG; UREA; UVARIA CHAMAE EXTRACT; ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE BLOOD LEVEL; STREPTOZOCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; LIVER PROTECTION; MALE; NONHUMAN; PANCREAS ISLET; PLANT ROOT; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA BLOOD LEVEL; UVARIA; UVARIA CHAMAE; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HUMAN; LIVER; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; LIVER; MALE; PLANT EXTRACTS; PLANT ROOTS; RATS; STREPTOZOCIN; UVARIA;

EID: 84999287099     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-016-1450-0     Document Type: Article

References (41)

1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
2. Kumar P, Clark M. Diabetes mellitus and other disorders of metabolism. Kumar and Clark's Clinical Medicine. 6th ed. Philadelphia: Elsevier Saunders; 2005. p. 1101-51.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of Diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
4. Sudha P, Zinjarde SS, Bhargava SY, Kumar AR. Potent α-amylase inhibitory activity of Indian Ayurvedic medicinal plants. BMC Complement Altern Med. 2011;11:5. doi: 10.1186/1472-6882-11-5.
5. Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, del Canizo-Gomez FJ. Type2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5:444-70.
6. Williams G. Management of non-insulin dependent Diabetes mellitus. Lancet. 1994;343:95-100.
7. Mallick C, Chatterjee K, GuhaBiswas M, Ghosh D. Antihyperglycemic effects of separate and composite extract of root of Musa paradisiacaand leaf of Cocciniaindicain streptozotocin induced diabetic male albino rat. Afr J Tradit Complement Altern Med. 2007;4:362-71.
8. Birru EM, Abdelwuhab M, Shewamene Z. Effect of hydroalcoholic leaves extract of IndigoferaSpicataForssk on blood glucose level of normal, glucose loaded and diabetic rodents. BMC Complement Altern Med. 2015;15:321. doi: 10.1186/s12906-015-0852-8.
9. Emordi JE, Agbaje EO, Oreagba IA, Iribhogbe OI. Preliminary phytochemical screening and evaluation ofhypoglycemic properties of the root extract of Uveriachamae. Bangladesh J Pharmacol. 2015;10:326-31.
10. Okwu DE, Iroabuchi F. Phytochemical Composition and Biological Activities of Uvariachamae and Clerodendoronsplendens. E-J Chem. 2009;6:553-60.
11. Okwuosa OM, Chukwura EI, Chukwuma GO, Okwuosa CN, Enweani IB, Agbakoba NR, et al. Phytochemical and antifungal activities of Uvaria Chamae leaves and roots, spondiasmombin leaves and bark and combretumracemosum leaves. Afr J Med Med Sci. 2012;41(suppl):99-103.
12. Osuagwu GGE, Ihenwosu AO. Phytochemical Composition and Antimicrobial Activity of the Leaves of Alchorneacordifolia (Schum and Thonn), Sansevieraliberica (GerandLabr) and Uvariachamae (P. Beauv). Am J Phytomed Clin Therap. 2014;2:1-12.
13. Okokon JE, Ita BN, Udokpo AE. The invivo antimalarial activities of uvariachamae and hippocratea Africana. Ann Trop Med and Parasitol. 2006;100:585-90.
14. Adelodun VO, Elusiayan CA, Olorunmola FO, Adewoyin FB, Omisore NO, Adepiti AO, Agbedahunsi JM, Adewunmi CO. Afr J Tradit Complement Altern Med. 2013;10:469-76.
15. National Research Council (NRC). Guide for the care and use of laboratory animals. 8th ed. Washington, DC: The National Academies Press; 2011.
16. Srinivasan K, Ramarao P. Animal models in type2 diabetes research: an overview. Indian J Med Res. 2007;125:451-72.
17. Qinna NA, Badwan AA. Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats. Drug Des Devel Ther. 2015;9:2515-25.
18. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH. Assessing plasma lipid levels, body weight and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound FM-VP4, to gerbils. J Pharm Pharm Sci. 2001;4:228-34.
19. Crook MA. Clinical Chemistry and Metabolic Medicine. 7th ed. London: Hodder Arnold; 2006.
20. Horder M, Sampson EJ. Approved IFCC recommendation on methods for the measurement of catalytic concentration of enzymes Part 7: IFCC method for creatinine Kinase (ATP: Creatine N-phosphotransferase, EC. 2. 7. 3. 2). Eur J Clin Chem Clin Biochem. 1991;29:435-56.
21. Hussain A, Eshrat HM. Hypoglycemic, hypolipidemic and antioxidant properties of combination of Curcumin from Curcuma longa, Linn and partially purified product from Abromaaugusta, Linn. in streptozotocin induced diabetes. Indian J Clin Biochem. 2002;17:33-43.
22. Grizzle WE, Fredenburgh JL, Myers RB. Fixation of tissues. In: Bancroft JD, Gamble M, editors. Theory and practice of Histological techniques. 6th ed. Philadelphia: Churchill Livingstone, Elsevier Limited; 2008. p. 53-74.
23. Sarkar S, Balhara Y. Diabetes mellitus and Suicide. Indian J Endocrinology Met. 2014;18:468-74.
24. Nordestgaard BG, Stender S, Kjeldsen K. Reduces artherogenesis in cholesterol fed Diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arterioscler. 1988;8:421-8.
25. Barrett- Connor EL, Cohn BA, Wingard DL Edelstein SL. Why is Diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in man ? The Rancho Bernardo study. JAMA. 1991;265:627-31.
26. Park JM, Bong HY, Jeong HI, Kim YK, Kim JY, Kwon O. Postprandial hypoglycemic effect of mulberry leaves in Gotokakizaki rats and counterpart control Wistar rats. Nutr Res Pract. 2009;3:272-8.
27. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. ClinTher. 2007;29:763-77.
28. Heidrich JE, Contos LM, Hunsaker LA, Deck LM, Vander Jagt DL. Inhibition of pancreatic cholesterase reduces cholesterol absorption in the hamster. BMC Pharmacol. 2004; doi: 10.1186/1471-2210-4-5
29. Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today. 2007;12:879-89.
30. Gotto Jr AM, Grundy SM. Lowering LDL Cholesterol: Questions From Recent Meta-Analyses and Subset Analyses of Clinical Trial Data Issues From the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. Circulation. 1999;99:1-7.
31. Kashyap SR, Defronzo RA. The Insulin resistance syndrome: physiological considerations. Diabetes Vasc Dis Res. 2007;4:13-9.
32. William M, Stephen B. The kidneys. Clinical chemistry. 6th ed. Philadephia: Mosby Elsevier; 2008. p. 69-93.
33. Lamb E, Neuwman DJ, Price C. Kidney function tests. In: Burtis CA, Ashwood ER, Burns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. Philadelphia: Elsevier Saunders; 2006. p. 797-835.
34. Parvizi MR, Parviz M, Tavangar SM, Soltani N, Kadkhodaee M, Seifi B, et al. Protective effect of magnesium on renal function in STZ-induced diabetic rats. J DiabetMetab Dis. 2014;13:84.
35. Panteghini M, Bais R, van Solinge WW. Enzymes. In: Burtis CA, Ashwood ER, Burns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. Philadelphia: Elsevier Saunders; 2006. p. 597-643.
36. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther. 2009;85:331-4.
37. Coates P. Liver function tests. Aust Fam Physician. 2011;40:113-5.
38. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut. 1999;45:129-33.
39. Harris EH. Elevated liver function tests in type 2 diabetes. Clin Diabetes. 2005;23:115-9.
40. Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabetes Med. 2009;26:1235-41.
41. Hollander P. Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People with Diabetes. Diabetes Spectrum. 2007;20:159-65.